biostudies-literatureUnknown2022Wang R<h4>Objective</h4>Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). In particular, there is a lack of rigorous trials of randomized controlled designs. In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail.<h4>Methods</h4>Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). Endoscopy and histology scores were evaluated as the primary outcome measure. The <i>Helicobacter pylori</i> positive rate and the disappearance rate of symptoms were also measuredEvidence-based complementary and alternative medicine : eCAM2266023https://www.ebi.ac.uk/biostudies/studies/S-EPMC9010182biostudies-literatureEfficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial.PMC9010182Rong WJing JHe TTian MWang RCui YLu ZMa XWang YWang ZYuan ZZhao YfalseEfficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial.<h4>Objective</h4>Zuojin pill (ZJP) is used as the classical prescription for a wide variety of digestive diseases. However, there is a lack of direct evidence for its use in the treatment of chronic nonatrophic gastritis (CNG). In particular, there is a lack of rigorous trials of randomized controlled designs. In this study, a randomized active-controlled clinical trial was performed to verify the efficacy and safety of ZJP in detail.<h4>Methods</h4>Patients with CNG were divided into the ZJP group and the Marzulene-S granule group. Patients were enrolled from September 2019 to February 2021 (ChiCTR2000040549). Endoscopy and histology scores were evaluated as the primary outcome measure. The <i>Helicobacter pylori</i> positive rate and the disappearance rate of symptoms were also measured2022-01-01T00:00:00Z20222025-04-25T22:58:00.185Z2025-04-06T09:14:29.435ZS-EPMC90101823543256610.1155/2022/2266023